DSIP (delta sleep-inducing peptide)
DSIP is a nine-amino-acid peptide isolated in 1977 and sold today for sleep. In July 2026 it was the one compound of seven that an FDA advisory committee voted against allowing pharmacies to compound.
- Legal lane: not FDA-approved. Advisory committee voted against adding it to the compounding list.
- Evidence grade: C
- Form: injection under the skin
- Also called: emideltide
What it is
Delta sleep-inducing peptide was named for its apparent effect on slow-wave, or delta, sleep in early animal work. It is marketed for insomnia and, less often, for opioid withdrawal.
What the evidence shows
The human literature is old, small and inconsistent. Studies from the 1980s and 1990s in insomnia and withdrawal reported mixed results in small groups, and no modern controlled trial has settled the question. The FDA's own review concluded the evidence was not sufficient.
Legal status
At the July 24, 2026 advisory committee meeting, seven peptides were reviewed for the list that licensed pharmacies may compound. Six were recommended for inclusion. DSIP was the exception, voted down 6 to 7 with one abstention. It was not part of the October 2026 policy, so it remains unapproved and without a legal compounding route.
Reported dosing
No dose has been established in human trials. We do not publish figures for compounds where no trial, label or prescriber practice supports one.
Safety
- Long-term human safety has not been characterized.
- Product sold outside a pharmacy has no verified identity, purity or sterility.
- Persistent insomnia has treatments with real evidence behind them, starting with cognitive behavioral therapy for insomnia. A clinician is the better first stop.